436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib

Authors :: T. Sahmoud
L. Vittori
Cristian Massacesi
C. Manlius
Ruth O'Regan
Luca Gianni
F. Andre
Florence Dalenc
Yunyu Zhang
M. Campone
Source :: European Journal of Cancer Supplements. 8:186
Publication Year :: 2010
Publisher :: Elsevier BV, 2010.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Everolimus
business.industry
Lapatinib
medicine.disease
Metastatic breast cancer
Trastuzumab
Internal medicine
medicine
In patient
business
medicine.drug

Full Text Access

Tools